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Title 
Characterization of Small Renal Tumors with MR Elastography: a Feasibility Study 
Abstract 
Objectives 
To explore the feasibility of magnetic resonance elastography (MRE) for characterizing 
indeterminate small renal tumors (SRT) as part of a multiparametric MR imaging protocol. 
Materials and Methods 
Following institutional review board approval and informed consent, 21 prospective adults 
(15 men, median age 55 [range 25-72] years) with SRT were enrolled. Tumors (2 – 5 cm Ø) 
were imaged using three-directional, gradient echo MRE. Viscoelastic parametric maps 
(shear wave velocity [c] and attenuation [α]) were analyzed by two independent 
radiologists. Interobserver agreement (Bland-Altman statistics and intraclass correlation 
coefficients [ICC]) was assessed. Anatomical T2-weighted, dynamic contrast enhanced (DCE) 
and diffusion sequences completed the acquisition protocol. Imaging parameters were 
compared between groups (Mann-Whitney U test). 
Results 
MRE quality was good in 18 cases (mean non-linearity <50%), including one papillary renal 
cell carcinoma and one metanephric adenoma. A cohort of 5 oncocytomas and 11 clear-cell 
renal cell carcinomas (ccRCC) was analyzedanalyzed for statistical differences. MRE 
viscoelastic parameters were the strongest imaging discriminators: oncocytomas displayed 
Revised manuscript with changes indicated (BLINDED)
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significantly lower shear velocity c (median, 0.77 m/s; interquartile range [IQR], 0.76-0.79) 
(P = 0.007) and higher shear attenuation α (median, 0.087 mm-1; IQR, 0.082-0.087) (P = 
0.008) than ccRCC (medians, 0.92 m/s and 0.066 mm-1; IQR, 0.84-0.97 and 0.054-0.074 
respectively). T2 signal intensity ratio (tumor/renal cortex) was lower in oncocytomas (P = 
0.02). DCE and diffusion MR parameters overlapped substantially (P ≥ 0.1). Oncocytomas 
displayed a consistent MRE viscoelastic profile, corresponding to data point clustering in a 
bidimensional scatter plot. MRE ICC were 0.982 for c and 0.984 for α, indicating excellent 
interobserver agreement. 
Conclusions 
MRE is feasible for SRT characterization; MRE viscoelastic parameters were stronger 
discriminators between oncocytoma and ccRCC than anatomical, DCE and diffusion MR 
imaging parameters. 
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Introduction 
Small indeterminate renal tumors (SRT), defined as solid enhancing renal lesions measuring 
up to 4 cm in diameter, pose a growing challenge to clinical practice (1, 2). Renal cell 
carcinoma (RCC) accounts for the majority of cases but up to 20% of SRT are benign (3). A 
recent estimate suggests that ~5600 benign renal tumors undergo surgical resection yearly 
in the US (4). Image-guided biopsy is performed increasingly to confirm the diagnosis 
preoperatively (5). Despite providing excellent concordance with surgical histology (6), 
biopsy is invasive and non-diagnostic in up to 20% of cases (7). A reliable, non-invasive 
imaging strategy to distinguish benign from malignant SRT would be advantageous, mostly 
so in patients with multiple comorbidities, and potentially cost effective. 
Anatomical and functional MR imaging parameters have shown potential individually to 
discriminate benign SRT from specific types of RCC (8-16), but their combined diagnostic 
accuracy has not been investigated in a prospective series to date. Oncocytoma and solid 
clear cell RCC (ccRCC), respectively the most common benign and malignant indeterminate 
SRT, share structural and physiological traits (high water content, prominent stroma, dense 
vascularity) that make their distinction by anatomical and functional MR imaging challenging 
in many cases (11, 12).  
Yet their pathological gross appearance and microscopic structure clearly differ (17, 18): 
oncocytomas are typically homogenous lesions with frequent central scarring and absent 
necrosis; microscopically, they are composed of tight cellular nests surrounded by myxoid 
stroma. Clear cell RCC have a variegated appearance consisting of soft yellow material 
alternating with areas of hemorrhage, fibrosis, necrosis and cystic degeneration; 
microscopically, they are composed of lipid- and glycogen-rich cells surrounded by an 
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extensive capillary network. Oncocytomas have no recognized malignant transformation 
potential and, once diagnosed, conservative management is safe (19). 
MR Elastography (MRE) is an emerging technique that evaluates soft tissue’s viscoelastic 
properties by measuring the shear waves produced by a vibrating mechanical transducer 
(20). It has been readily incorporated into clinical MR imaging protocols and has been 
employed successfully in the assessment of hepatic fibrosis (21, 22) and for lesion 
characterization in the liver, central nervous system and breast (23-26). 
We hypothesized that the viscoelastic shear properties of SRT measured by MRE would 
reflect the underlying tumor composition (e.g. cellular density, extracellular collagen, 
hemorrhage, necrosis) and architecture (e.g. cellular and connective tissue distribution, 
vascular size, density and permeability) and therefore differ between histopathological 
groups. In this study, we aimed to explore the feasibility and diagnostic potential of MRE, 
performed as part of a multiparametric MR imaging protocol, for characterizing 
indeterminate small renal tumors (SRT) in patients scheduled for surgery. 
Materials and Methods 
Participants 
This prospective feasibility study was conducted between August 2015 and October 2016, 
following approval by the national research ethics committees; informed written consent 
was obtained from all subjects. 
Twenty-one patients (15 men and 6 women) with a median age of 55 years (range, 25 to 72 
years) and median BMI of 27.0 (range, 19.0 to 29.4), were recruited from a tertiary-care 
urological clinic. Patients were potentially eligible if under consideration for surgical 
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resection (partial or total nephrectomy) of an indeterminate solid renal mass measuring ≤5 
cm in maximum diameter on cross-sectional imaging. Exclusion criteria were standard 
contraindications to contrast enhanced MR imaging (e.g. cardiac pacemaker, cochlear 
implant, significant renal impairment i.e. eGFR <50 mL/min or serum creatinine > 180 
μmol/L). 
MR Imaging Acquisition 
MR imaging was performed on a 3.0 Tesla system (Biograph mMR, Siemens Healthcare 
GmbH, Erlangen, Germany).  ItThe protocol included MRE, anatomical T1 and T2 weighted 
sequences, dynamic contrast enhanced (DCE) MRI and diffusion-weighted imaging. Patients 
lied supine (head first) in the scanner and fasted for 4 hours before imaging. 
MRE Acquisition 
Mechanical vibrations were generated at a frequency of 30 Hz and at 70% of the maximum 
power by a remote loudspeaker (Resoundant®) and transmitted via compressed air to a 
disc-shaped passive transducer applied over the patient’s flank of interest (mid-axillary line, 
held in place by an elastic band). A frequency of 30 Hz was selected as a compromise 
between resolution and efficient wave penetration in the retroperitoneum. MRE was based 
upon a prototype 2D multi-slice interleaved gradient echo sequence synchronized with the 
transducer's vibrations (27): repetition time, 11.11 ms (3 shots with a vibration frequency of 
30Hz, corresponding to a period of 33.33 ms); echo time, 7.38 ms; motion encoding gradient 
amplitude, 30 mT/m; GRAPPA parallel imaging acceleration factor, 2; FOV, 265 x 385 mm. 
Four acquisitions in consecutive expiratory breath holds of 17 s (corresponding to 3 motion-
encoding directions and one reference measurement without motion encoding) provided 
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MRE data within 6 consecutive slices of 128 x 88 pixels at 3 mm isotropic resolution and 4 
wave phase offsets. Measurements were performed at mid-tumor level and repeated in 1 or 
2 normal portions of the same kidney (standardized to either upper pole, mid-kidney or 
lower pole), in order to obtain reference measurements from healthy renal parenchyma. 
Each MRE measurement had an approximate duration of 2 minutes. 
MRE Reconstruction 
MRE reconstruction used firstly the application of the curl operator for removal of the 
compressional component, secondly a direct inversion of the Helmholtz equation (28). 
Parametric maps of shear wave velocity (c), a measure of tissue elasticity, and attenuation 
(α), a measure of viscosity, were generated offline using dedicated in-house software, 
validated previously (28-30). 
Data post-processing was performed by a physicist with over 20 years of experience in MRE. 
Tumor data analysis was performed independently by two board-certified radiologists with 
over 7 years of experience in abdominal MR imaging (MRE observer 1 and 2), blinded to 
histopathology results. Normal kidney measurements were performed by a single 
radiologist (MRE observer 1). 
Free-hand regions of interest (ROI) were drawn around each tumor and around normal 
renal parenchyma (including both cortex and medulla, aiming to match the size of tumor 
ROI) on the two contiguous central slices of magnitude images, with reference to the 
available anatomical sequences, and transposed automatically via geometrical 
mappingcopied onto the two contiguous central slices of parametric maps. The mean and 
standard deviation of the quantified parameters were recorded for each case. 
7 
 
MRE Quality Assessment 
Parametric maps of data ‘non-linearity’, displaying the percentage deviation of the phase 
signal from a perfect sinusoidal modulation, were assessed by both readers for each MRE 
measurement, using the same ROI as previously, and the mean ‘non-linearity’ percentage 
documented. A threshold of <50% mean ‘non-linearity’ was defined as acceptable data 
quality. 
Anatomical and Functional MR Imaging 
Anatomical imaging included a T2-weighted half-Fourier single-shot turbo spin echo 
sequence (HASTE) (TR, 1000 msec; TE, 97 msec; FA, 135°; NEX, 1; GRAPPA parallel imaging 
acceleration factor, 2; FOV, 384 x 250 mm; pixel size, 1.5 x 1.2 x 3.0 mm) acquired in the 
axial plane.  
Dynamic contrast-enhanced (DCE) MR imaging was based on a 3D T1-weighted axial 
volumetric interpolated spoiled gradient echo sequence (VIBE) (TR, 4.62 msec; TE, 1.72 
msec; FA, 18°; number of signals acquired, 1; parallel imaging acceleration factor, 2; FOV, 
300 x 244 mm; pixel size, 1.8 x 1.3 x 4.0 mm). 0.1 mmol/kg of gadolinium contrast agent was 
administered intravenously (Gadovist®, Bayer) at a rate of 4 mL/sec using a power injector, 
followed by a 20 mL saline chaser; 30 volumes were acquired post contrast injection over 3 
minutes, resulting in a temporal resolution of 6.4 sec. The dynamic acquisition was preceded 
by a T1 calibration sequence with the same parameters except a flip angle of 3°. 
Diffusion-weighted imaging consisted of free-breathing single-shot echo-planar imaging in 
the axial plane with b values of 50, 500 and 800 mm2/sec. Imaging parameters were as 
follows: TR, 6100 msec; TE, 62 msec; NEX, 5; parallel imaging acceleration factor, 2; FOV, 
380 x 285 mm; pixel size 3.7 x 3.0 x 4.0 mm.  
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Anatomical and functional sequences were post processed and analyzed offline on a 
commercial platform (Multimodality Workplace, Siemens). All quantitative measurements 
were performed by a single radiologist (DP)(MRE observer 1), blinded to histopathology. 
Freehand ROI were drawn on each slice displaying the lesion of interest; volumetric means 
were analyzed. T2 signal intensity (SI) ratio was calculated as the % ratio of tumor over renal 
cortex on the T2 HASTE sequence (8). 
DCE MR imaging parametric maps, including transfer coefficient (Ktrans), rate constant (kep), 
extracellular-extravascular space fractional volume (ve) and initial area under the 
concentration curve for the first 60 seconds (iAUC60), were generated on dedicated software 
(Tissue 4D; Siemens); nonrigid motion correction and registration to the calibration 
sequence were applied to the dynamic acquisition; quantification was based on the two-
compartment Tofts model (31), using a pre-set population averaged arterial input function. 
Apparent diffusion coefficient (ADC) maps were generated by fitting a mono-exponential 
function to all b values.  
Statistics 
All statistical analyses were performed using IBM SPSS version 23.0 software. Continuous 
variables were regarded as non-normally distributed and expressed as medians and 
interquartile range. Measurements were compared between the two main histological 
groups using the non-parametric Mann-Whitney U test. Mean interobserver MRE values 
were used in the analysis. P < .05 was considered indicative of a significant difference. 
Interobserver agreement was assessed using Bland-Altman (BA) statistics and intraclass 
correlation coefficients (ICC). MRE within-subject variability in healthy renal parenchyma 
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was expressed in terms of mean differences and coefficients of variance (CV). Missing data 
were omitted from the analysis. 
Results 
One patient did not complete imaging due to claustrophobia, leaving 20 complete imaging 
datasets including MRE. Surgical histopathology became available for 19 patients and 
revealed 4 renal oncocytomas, 12 ccRCC (1, Fuhrman grade 3; 8, grade 2; 3, grade 1), 2 
papillary RCC and 1 metanephric adenoma. One further case of renal oncocytoma was 
diagnosed from image-guided biopsy and surgery was deferred. Tumor diameters ranged 
between 2.2 and 5.0 cm. All imaging sessions were completed in less than 60 minutes. 
MRE of Tumors 
Two tumor MRE datasets were excluded for insufficient quality, secondary to poor patient 
compliance with breath hold instructions and consequent high data non-linearity (>50%), 
leaving a cohort of 11 clear cell renal cell carcinomas (ccRCC) and 5 oncocytomas for 
statistical analysis. 
Shear wave velocity c was significantly lower in oncocytomas (median, 0.77 m/s; 
interquartile range (IQR), 0.76-0.79) than in ccRCC (median, 0.92 m/s; IQR, 0.84-0.97) (P = 
0.007). Shear wave attenuation α was significantly higher in oncocytomas (median, 0.087 
mm-1; IQR, 0.082-0.087) than in ccRCC (median, 0.066 mm-1; IQR, 0.054-0.074) (P = 0.008). 
Complete results, including case-by-case mean values and standard deviations, are reported 
in Table 1. Pictorial examples are shown in Figure 1. Oncocytomas displayed a relatively 
narrow range of values (c range, 0.71-0.83 m/s; α range, 0.082-0.093 mm-1), corresponding 
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to data point clustering in a bidimensional scatter plot (Figure 2). ccRCC had wider ranges (c 
range, 0.79-1.11 m/s; α range, 0.046-0.083 mm-1), resulting in a broader data point scatter. 
The only papillary RCC imaged with sufficient data quality showed relatively low c (0.77 m/s, 
coinciding with the median value of oncocytomas) and low α (0.064 mm-1, close to the 
median of ccRCC). Metanephric adenoma displayed relatively low c (0.78 m/s) and 
intermediate α (0.079 mm-1). 
MRE Interobserver Agreement 
Mean ROI size was 226 ± 109 pixels for observer 1 and 196 ± 102 pixels for observer 2. 
Mean differences in tumors were 0.002 m/s [c] and -0.0005 mm-1 [α]. Bland-Altman limits of 
agreement were the mean differences as previously ± 0.055 m/s [c] and ± 0.0077 mm-1 [α] 
respectively (Figure 3). ICC (95% confidence intervals) were 0.982 (0.953-0.993) [c] and 
0.984 (0.957-0.994) [α], indicating excellent agreement. 
MRE of Normal Kidney 
A total of 31 MRE measurements of acceptable quality were performed in normal portions 
of the tumor-containing kidneys. Mean shear velocity c in the renal parenchyma was 0.89 ± 
0.10 m/s; mean shear attenuation α was 0.072 ± 0.012 mm-1. 
Two separate measurements in different portions of the same kidney were acquired in a 
subset of 10 patients. Mean within-subject differences were 0.10 ± 0.05 m/s for c and 0.014 
± 0.010 mm-1 for α, corresponding to CV of 7.81 ± 4.61% and 14.24 ± 10.72% respectively. 
Anatomical and Functional MR Imaging of Tumors 
Tumor parametric values are reported in Table 1. Oncocytomas had significantly lower T2 SI 
ratio (median, 93%; interquartile range, 89-93%) than ccRCC (median, 120%; interquartile 
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range, 103-128%) (P = 0.020). No statistically significant difference between the two 
histological groups was observed among functional MR imaging parameters. Oncocytomas 
appeared on average more vascular on DCE MR imaging, with higher iAUC60 (median, 59 
mmol; P = 0.100), Ktrans (median, 0.24 min-1; P = 0.126), kep (median, 0.66 min-1; P = 0.193) 
and lower ve (median, 0.30 mL/100 mL; P = 0.692). ADC varied considerably within both 
groups, being on average lower in oncocytomas (median, 1363 x 10-6 mm2/s) (P = 0.193). 
Both papillary RCC displayed markedly restricted diffusion (ADC = 839 and 959 x 10-6 mm2/s) 
and low T2 SI ratios (74% and 55%), in line with the existing literature (32, 33). The 
metanephric adenoma showed relatively low T2 SI ratio (58%) and contrast enhancement 
(iAUC60 = 19 mmol)(34). Only partial data point clustering was obtained by plotting T2 SI 
ratio against ADC (Figure 2B). No clustering was observed by plotting DCE MR Ktrans against 
ve (Figure 2C). 
Among qualitative anatomical tumor features, a T2 pseudocapsule was present in 2 out of 5 
oncocytomas and 10 out of 12 ccRCC; central T2 hyperintensity was observed in 3 
oncocytomas and 1 ccRCC; and signal drop on opposed-phase chemical shift MRI in no 
oncocytoma and 7 ccRCC. 
Discussion 
Our study shows that MRE is feasible, as part of a multiparametric MR protocol, for the 
characterization of small indeterminate renal tumors and represents a promising technique 
for distinguishing benign oncocytoma from malignant clear cell carcinoma. MRE shear 
velocity c and shear attenuation α were the strongest imaging discriminators between 
oncocytoma and ccRCC in this initial prospective cohort of 20 patients. 
12 
 
Identifying renal oncocytoma among indeterminate SRT is problematic based on imaging 
alone, even using multiparametric MR, as highlighted by current literature. Among 
anatomical MR imaging parameters, T2 signal intensity has been shown to be higher in 
ccRCC than in oncocytoma and chromophobe RCC, but the overlap is substantial (35, 36). T2 
SI ratio was in fact the third best discriminator between oncocytoma and ccRCC in our study. 
The presence of a central area of T2 signal hyperintensity, compatible with necrosis or 
fibrosis, can be observed in both oncocytoma and RCC (8, 9). Chemical shift MR, combined 
with delayed contrast enhanced imaging, has been found to have a high negative predictive 
value for oncocytoma (97%), by revealing the typical absence of fat and the presence of 
enhancing central fibrosis: these findings, however, have yet to be validated prospectively 
(10). A T2 hypointense pseudocapsule, commonly observed in SRT, is also nonspecific (16). 
Diffusion and contrast enhancement characteristics can discriminate between types of RCC 
but again are known to overlap between oncocytoma and ccRCC (32, 37); this was the case 
in our cohort, where DCE MR iAUC60 was the strongest functional discriminator (P = .10), 
being higher in oncocytomas. Taouli et al. previously found significantly lower ADC values in 
solid ccRCC than in oncocytomas, but only after excluding Bosniak 4 ccRCC (i.e. solid masses 
with a large cystic or a necrotic component), potentially indistinguishable from oncocytoma 
in our experience (11). No significant signal intensity change was observed by Vargas et al. 
on contrast-enhanced MR between ccRCC and oncocytoma in any phase of enhancement 
(12). 
To our knowledge, this study is the first to investigate the viscoelastic properties of SRT 
using MRE. Published reports employing semiquantitative (strain) or quantitative (shear-
wave) ultrasound elastography techniques for differentiating benign from malignant renal 
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tumors found RCC to be stiffer than benign lesions such as angiomyolipoma; no 
oncocytomas were included, however (38-40). 
Our results support the hypothesis that differences in tumor composition and structural 
architecture, clearly distinguishable on histopathology between oncocytoma and RCC, are 
reflected by MRE viscoelastic shear properties. Oncocytomas showed lower shear wave 
velocity, corresponding to lower stiffness (storage modulus), and higher shear attenuation 
(loss modulus), corresponding to higher viscosity, than ccRCC.  This is in line with the 
evidence that malignancy increases stiffness through collagen deposition in the extracellular 
matrix and raised interstitial pressure levels from the altered vasculature (41, 42). Lower 
MRE stiffness values in benign versus malignant tumors have been documented in the 
breast and in the liver (23, 26, 43, 44). 
Few studies to date have assessed tumors in terms of shear wave attenuation. The loss 
modulus was found to be significantly higher in hepatocellular carcinoma than in benign 
liver tumors (hemangioma, focal nodular hyperplasia, adenoma) by Garteiser et al. (23), 
contrasting with our results. We speculate that the higher shear wave attenuation values 
measured in oncocytoma might reflect a high density of capillaries with normal 
endothelium, resulting in efficient energy dispersion in the form of heat and contrasting 
with the disorganized vasculature and leaky endothelium typical of renal carcinomas.  
Propagating waves could be appreciated on phase images in all MRE acquisitions. Two out 
of 20 datasets were excluded for insufficient quality, defined as nonlinearity >50%. In one 
case (ccRCC-07, Table 1), respiratory motion was identified as the main causative factor 
from the presence of blurred renal contours on the magnitude images. In the second case 
(papRCC-02) (Figure 4), wave penetration inside the lesion was poorinconsistent with an 
incompressible material (as if detached from the surrounding tissue) inside the lesion 
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despite good penetration in the adjacent kidney; this was a hemorrhagic papillary RCC , 
showing marked signal hypointensity on T2 HASTE. Interestingly, one of the main causes 
identified by Wagner et al. for technical MRE failure in the liver at 3T (45) was hepatic iron 
deposition, causing shortening of T2* relaxation. Intratumoral hemorrhage is frequent in 
papillary RCC, but is not known to occur in oncocytoma; low ADC values are the dominant 
MR feature of papillary RCC and in our experience it seems unlikely that MRE will be the 
main determinant for papillary RCC characterization. 
The average level of phase signal nonlinearity was ~30% throughout MRE acquisitions, 
corresponding to our previous clinical experience using the Resoundant® system in the 
upper abdomen. New bespoke transducers, based upon a gravitational concept for 
generating shear waves (46), are expected to lower this level and thereby increase the 
reproducibility of viscoelastic parameters. MRE interobserver limits of agreement (mean 
difference ± 0.055 m/s [c] and ± 0.0077 mm-1 [α]) were deemed within acceptable limits and 
appear unlikely to affect the significance of between-group differences.  
Of the two MRE parameters, c was less dispersed around the mean value in tumor ROI: SD 
ranged between 0.11 and 0.30 m/s (Table 1), corresponding to a CV of ~14-28%. MRE c SD 
were noticeably lower in oncocytomas than ccRCC; this was not the case for MRE α or 
anatomical/functional MR imaging parameters. Within-subject variability in healthy renal 
parenchyma was 7.81 ± 4.61% for c and 14.24 ± 10.72% for α. Similarly, Rouviere et al. (47) 
found a mean shear wave velocity variation of 6% (range, 2 - 16%) between two 
independent measurements in the kidney of young healthy adults at 45 Hz, also using a 
gradient echo sequence at 1.5 T. Although not directly comparable, a recent meta-analysis 
on MRE repeatability in the liver identified a measured change in hepatic stiffness of 22% or 
greater as a reliable true change (95% confidence) (48). 
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Despite our promising results, our study does have limitations: the small study cohort 
reflects its exploratory nature and does not allow us to draw definitive conclusions on the 
diagnostic accuracy of MR imaging parameters. Prospective recruitment of consecutive 
patients from a single tertiary clinic meant that only the most common SRT histologies were 
captured. The decision to include tumors ≤ 5 cm in diameter (contrasting with the 
conventional definition of small renal mass, ≤ 4 cm) was made to facilitate patient 
recruitment. Less common histologies such as chromophobe RCC, often morphologically 
indistinguishable from oncocytoma (36), and fat poor AML (35) were not part of our 
prospective cohort. 
In conclusion, MRE is feasible and practicable for the characterization of small 
indeterminate renal tumors as part of a multiparametric MR protocol. This feasibility study 
highlights the diagnostic potential of MRE for distinguishing renal oncocytoma from ccRCC, 
strengthening the case for confirmation of these results in a powered diagnostic accuracy 
study. 
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Tables 
Table 1. Results from tumor multiparametric MR imaging, displayed by tumor histology.  
Note. Tumor diameters as measured at surgical histopathology. Mean values ± standard 
deviation. P values for between-group comparisons were determined with the Mann-
Whitney U test. IQR = interquartile range. - = missing value. 
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Case # Diameter (cm) c (m/s) α (mm-1) iAUC60 (mmol) Ktrans (min-1) Kep (min-1) Ve (mL/100 mL) T2 SI RATIO (%) 
ADC (10-6 x 
mm2/s) 
RENAL ONCOCYTOMA 
ONCO-1 4.2 0.83 ± 0.16 0.093 ± 0.033 72 ± 34 0.31 ± 0.17 0.99 ± 0.37 0.30 ± 0.14 93 ± 30 1949 ± 338 
ONCO-2 5.0 0.79 ± 0.16 0.082 ± 0.035 32 ± 16 0.09 ± 0.05 0.32 ± 0.16 0.28 ± 0.15 86 ± 27 1319 ± 260 
ONCO-3 5.0 0.77 ± 0.14 0.082 ± 0.048 80 ± 38 0.41 ± 0.24 1.15 ± 0.58 0.33 ± 0.17 89 ± 24 1348 ± 284 
ONCO-4 3.1 0.76 ± 0.11 0.087 ± 0.044 59 ± 22 0.24 ± 0.10 0.62 ± 0.23 0.39 ± 0.14 124 ± 40 1961 ± 315 
ONCO-5 4.5 0.71 ± 0.11 0.087 ± 0.042 51 ± 32 0.20 ± 0.13 0.66 ± 0.26 0.29 ± 0.16 93 ± 30 1363 ± 231 
Median (IQR) 4.5 (4.2-5.0) 
0.77 (0.76-
0.79) 
0.087 (0.082-
0.087) 
59 (51-72) 0.24 (0.20-0.31) 0.66 (0.62-0.99) 0.30 (0.29-0.33) 93 (89-93) 
1363 (1348-
1949) 
CLEAR CELL RENAL CELL CARCINOMA 
ccRCC-01 3.3 1.00 ± 0.28 0.060 ± 0.027 29 ± 20 0.11 ± 0.09 0.47 ± 0.30 0.24 ± 0.17 126 ± 40 1760 ± 326 
ccRCC-02 3.0 0.79 ± 0.12 0.072 ± 0.054 63 ± 29 0.21 ± 0.10 0.51 ± 0.15 0.40 ± 0.17 106 ± 23 1590 ± 184 
ccRCC-03 3.6 0.83 ± 0.16 0.070 ± 0.040 50 ± 43 0.19 ± 0.20 0.41 ± 0.36 0.33 ± 0.30 101 ± 34 1695 ± 365 
ccRCC-04 2.8 0.94 ± 0.19 0.066 ± 0.035 55 ± 34 0.22 ± 0.17 0.74 ± 0.46 0.29 ± 0.17 102 ± 31 1722 ± 320 
ccRCC-05 2.5 0.84 ± 0.23 0.083 ± 0.045 46 ± 32 0.17 ± 0.13 0.33 ± 0.23 0.45 ± 0.26 141 ± 44 2118 ± 394 
ccRCC-06 3.0 0.86 ± 0.18 0.085 ± 0.030 23 ± 22 0.09 ± 0.09 0.63 ± 1.42 0.18 ± 0.17 121 ± 37 1929 ± 303 
ccRCC-07 2.7 - - 62 ± 44 0.24 ± 0.18 0.62 ± 0.38 0.33 ± 0.23 94 ± 32 1433 ± 255 
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ccRCC-08 3.5 1.11 ± 0.30 0.052 ± 0.032 27 ± 21 0.11 ± 0.09 0.30 ± 0.24  0.38 ± 0.27 152 ± 47 2483 ± 424 
ccRCC-09 4.2 0.92 ± 0.24 0.046 ± 0.033 61 ± 31 0.27 ± 0.16 0.71 ± 0.28 0.37 ± 0.20 124 ± 45 1512 ± 460 
ccRCC-10 4.0 0.93 ± 0.19 0.032 ± 0.022 47 ± 43 0.19 ± 0.18 0.68 ± 0.56 0.26 ± 0.24 104 ± 35 1795 ± 295 
ccRCC-11 3.4 1.00 ± 0.23 0.075 ± 0.050 29 ± 21 0.11 ± 0.09 0.38 ± 0.38 0.30 ± 0.19 120 ± 54 1984 ± 348 
ccRCC-12 2.2 0.80 ± 0.14 0.056 ± 0.028 51 ± 19 0.15 ± 0.07 0.30 ± 0.15 0.49 ± 0.22 134 ± 39 1612 ± 155 
Median (IQR) 3.2 (2.8-3.5) 
0.92 (0.84-
0.97) 
0.066 (0.054-
0.074) 
48 (29-57) 0.18 (0.11-0.21) 0.49 (0.36-0.64) 0.33 (0.28-0.39) 120 (103-128) 
1741 (1606-
1943) 
P value .017 .007 .008 .100 .126 .193 .692 .020 .193 
PAPILLARY RENAL CELL CARCINOMA 
papRCC-01 3.7 0.77 ± 0.10 0.062 ± 0.029 30 ± 20 0.11 ± 0.10 0.68 ± 0.40 0.17 ± 0.14 74 ± 17 839 ± 218 
papRCC-02 4.1 - - 15 ± 19 0.06 ± 0.04 0.50 ± 0.55 0.16 ± 0.10 55 ± 35 959 ± 602 
METANEPHRIC ADENOMA 
MA-01 5.0 0.78 ± 0.15 0.079 ± 0.033 19 ± 12 0.11 ± 0.07 0.17 ± 0.20 0.37 ± 0.21 58 ± 14 1222 ± 339 
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Figure Captions 
Figure 1. A. Fuhrman grade 2, 2.7 cm ccRCC in a 67-year-old man. B. 3.1 cm renal 
oncocytoma in a 51-year-old man. Axial MR imaging sections. Anatomical T2 HASTE (top 
left), ADC map (middle), cortico-medullary phase contrast-enhanced T1 VIBE (top right), 
MRE magnitude image (bottom left), MRE c (middle) and MRE α (bottom right) parametric 
maps. Morphological and functional imaging features are indistinguishable between the two 
histologies. Oncocytoma displays relatively lower shear velocity c and higher shear 
attenuation α. Tumors are contoured in red on MRE magnitude images and parametric 
maps. The adjacent kidney is contoured in pink and can be clearly distinguished from the 
surrounding structures on MRE shear velocity maps. 
Figure 2. Bidimensional scatter plots of tumor MR imaging parameters. Oncocytomas 
display a consistent MRE viscoelastic profile, corresponding to data point clustering (A). Only 
partial clustering is obtained by plotting T2 SI ratio against ADC (B). No clustering is 
observed by plotting DCE MR Ktrans against ve (C). 
Figure 3. Interobserver agreement. Bland-Altman graphs of MRE c (left) and α (right), 
plotting interobserver differences against their mean. Red dotted lines represent 95% 
Bland-Altman limits of agreement; blue line represents the mean difference. 
Figure 4. Type 1, 4.1 cm papillary RCC in a 66-year-old man: axial MR imaging sections. 
Anatomical T2 HASTE (left), MRE gradient-echo magnitude image (middle) and MRE non-
linearity parametric map (right). Intra-tumoral hemorrhagehaemorrhage, confirmed at 
histology, corresponds to low signal intensity in A and B.  MRE phase signal shows elevated 
non-linearity within the tumor (~80%) compared to adjacent renal parenchyma (~35%). 
Figure 1A Click here to download Figure Figure 1a - revised.png 
Figure 1B Click here to download Figure Figure1b - revised.png 
Figure 2 Click here to download Figure Figure 2 - revised.png 
Figure 3 Click here to download Figure Figure 3.png 
Figure 4 Click here to download Figure Figure 4.png 
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Title 
Characterization of Small Renal Tumors with MR Elastography: a Feasibility Study 
Abstract 
Objectives 
To explore the feasibility of magnetic resonance elastography (MRE) for characterizing 
indeterminate small renal tumors (SRT) as part of a multiparametric MR imaging protocol. 
Materials and Methods 
Following institutional review board approval and informed consent, 21 prospective adults 
(15 men, median age 55 [range 25-72] years) with SRT were enrolled. Tumors (2 – 5 cm Ø) 
were imaged using three-directional, gradient echo MRE. Viscoelastic parametric maps 
(shear wave velocity [c] and attenuation [α]) were analyzed by two independent 
radiologists. Interobserver agreement (Bland-Altman statistics and intraclass correlation 
coefficients [ICC]) was assessed. Anatomical T2-weighted, dynamic contrast enhanced (DCE) 
and diffusion sequences completed the acquisition protocol. Imaging parameters were 
compared between groups (Mann-Whitney U test). 
Results 
MRE quality was good in 18 cases (mean non-linearity <50%), including one papillary renal 
cell carcinoma and one metanephric adenoma. A cohort of 5 oncocytomas and 11 clear-cell 
renal cell carcinomas (ccRCC) was analyzed for statistical differences. MRE viscoelastic 
parameters were the strongest imaging discriminators: oncocytomas displayed significantly 
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lower shear velocity c (median, 0.77 m/s; interquartile range [IQR], 0.76-0.79) (P = 0.007) 
and higher shear attenuation α (median, 0.087 mm-1; IQR, 0.082-0.087) (P = 0.008) than 
ccRCC (medians, 0.92 m/s and 0.066 mm-1; IQR, 0.84-0.97 and 0.054-0.074 respectively). T2 
signal intensity ratio (tumor/renal cortex) was lower in oncocytomas (P = 0.02). DCE and 
diffusion MR parameters overlapped substantially (P ≥ 0.1). Oncocytomas displayed a 
consistent MRE viscoelastic profile, corresponding to data point clustering in a 
bidimensional scatter plot. MRE ICC were 0.982 for c and 0.984 for α, indicating excellent 
interobserver agreement. 
Conclusions 
MRE is feasible for SRT characterization; MRE viscoelastic parameters were stronger 
discriminators between oncocytoma and ccRCC than anatomical, DCE and diffusion MR 
imaging parameters. 
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Introduction 
Small indeterminate renal tumors (SRT), defined as solid enhancing renal lesions measuring 
up to 4 cm in diameter, pose a growing challenge to clinical practice (1, 2). Renal cell 
carcinoma (RCC) accounts for the majority of cases but up to 20% of SRT are benign (3). A 
recent estimate suggests that ~5600 benign renal tumors undergo surgical resection yearly 
in the US (4). Image-guided biopsy is performed increasingly to confirm the diagnosis 
preoperatively (5). Despite providing excellent concordance with surgical histology (6), 
biopsy is invasive and non-diagnostic in up to 20% of cases (7). A reliable, non-invasive 
imaging strategy to distinguish benign from malignant SRT would be advantageous, mostly 
so in patients with multiple comorbidities, and potentially cost effective. 
Anatomical and functional MR imaging parameters have shown potential individually to 
discriminate benign SRT from specific types of RCC (8-16), but their combined diagnostic 
accuracy has not been investigated in a prospective series to date. Oncocytoma and solid 
clear cell RCC (ccRCC), respectively the most common benign and malignant indeterminate 
SRT, share structural and physiological traits (high water content, prominent stroma, dense 
vascularity) that make their distinction by anatomical and functional MR imaging challenging 
in many cases (11, 12).  
Yet their pathological gross appearance and microscopic structure clearly differ (17, 18): 
oncocytomas are typically homogenous lesions with frequent central scarring and absent 
necrosis; microscopically, they are composed of tight cellular nests surrounded by myxoid 
stroma. Clear cell RCC have a variegated appearance consisting of soft yellow material 
alternating with areas of hemorrhage, fibrosis, necrosis and cystic degeneration; 
microscopically, they are composed of lipid- and glycogen-rich cells surrounded by an 
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extensive capillary network. Oncocytomas have no recognized malignant transformation 
potential and, once diagnosed, conservative management is safe (19). 
MR Elastography (MRE) is an emerging technique that evaluates soft tissue’s viscoelastic 
properties by measuring the shear waves produced by a vibrating mechanical transducer 
(20). It has been readily incorporated into clinical MR imaging protocols and has been 
employed successfully in the assessment of hepatic fibrosis (21, 22) and for lesion 
characterization in the liver, central nervous system and breast (23-26). 
We hypothesized that the viscoelastic shear properties of SRT measured by MRE would 
reflect the underlying tumor composition (e.g. cellular density, extracellular collagen, 
hemorrhage, necrosis) and architecture (e.g. cellular and connective tissue distribution, 
vascular size, density and permeability) and therefore differ between histopathological 
groups. In this study, we aimed to explore the feasibility and diagnostic potential of MRE, 
performed as part of a multiparametric MR imaging protocol, for characterizing 
indeterminate small renal tumors (SRT) in patients scheduled for surgery. 
Materials and Methods 
Participants 
This prospective feasibility study was conducted between August 2015 and October 2016, 
following approval by the national research ethics committees; informed written consent 
was obtained from all subjects. 
Twenty-one patients (15 men and 6 women) with a median age of 55 years (range, 25 to 72 
years) and median BMI of 27.0 (range, 19.0 to 29.4), were recruited from a tertiary-care 
urological clinic. Patients were potentially eligible if under consideration for surgical 
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resection (partial or total nephrectomy) of an indeterminate solid renal mass measuring ≤5 
cm in maximum diameter on cross-sectional imaging. Exclusion criteria were standard 
contraindications to contrast enhanced MR imaging (e.g. cardiac pacemaker, cochlear 
implant, significant renal impairment i.e. eGFR <50 mL/min or serum creatinine > 180 
μmol/L). 
MR Imaging Acquisition 
MR imaging was performed on a 3.0 Tesla system (Biograph mMR, Siemens Healthcare 
GmbH, Erlangen, Germany). The protocol included MRE, anatomical T1 and T2 weighted 
sequences, dynamic contrast enhanced (DCE) MRI and diffusion-weighted imaging. Patients 
lied supine (head first) in the scanner and fasted for 4 hours before imaging. 
MRE Acquisition 
Mechanical vibrations were generated at a frequency of 30 Hz and at 70% of the maximum 
power by a remote loudspeaker (Resoundant®) and transmitted via compressed air to a 
disc-shaped passive transducer applied over the patient’s flank of interest (mid-axillary line, 
held in place by an elastic band). A frequency of 30 Hz was selected as a compromise 
between resolution and efficient wave penetration in the retroperitoneum. MRE was based 
upon a prototype 2D multi-slice interleaved gradient echo sequence synchronized with the 
transducer's vibrations (27): repetition time, 11.11 ms (3 shots with a vibration frequency of 
30Hz, corresponding to a period of 33.33 ms); echo time, 7.38 ms; motion encoding gradient 
amplitude, 30 mT/m; GRAPPA parallel imaging acceleration factor, 2; FOV, 265 x 385 mm. 
Four acquisitions in consecutive expiratory breath holds of 17 s (corresponding to 3 motion-
encoding directions and one reference measurement without motion encoding) provided 
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MRE data within 6 consecutive slices of 128 x 88 pixels at 3 mm isotropic resolution and 4 
wave phase offsets. Measurements were performed at mid-tumor level and repeated in 1 or 
2 normal portions of the same kidney (standardized to either upper pole, mid-kidney or 
lower pole), in order to obtain reference measurements from healthy renal parenchyma. 
Each MRE measurement had an approximate duration of 2 minutes. 
MRE Reconstruction 
MRE reconstruction used firstly the application of the curl operator for removal of the 
compressional component, secondly a direct inversion of the Helmholtz equation (28). 
Parametric maps of shear wave velocity (c), a measure of tissue elasticity, and attenuation 
(α), a measure of viscosity, were generated offline using dedicated in-house software, 
validated previously (28-30). 
Data post-processing was performed by a physicist with over 20 years of experience in MRE. 
Tumor data analysis was performed independently by two board-certified radiologists with 
over 7 years of experience in abdominal MR imaging (MRE observer 1 and 2), blinded to 
histopathology results. Normal kidney measurements were performed by a single 
radiologist (MRE observer 1). 
Free-hand regions of interest (ROI) were drawn around each tumor and around normal 
renal parenchyma (including both cortex and medulla, aiming to match the size of tumor 
ROI) on the two contiguous central slices of magnitude images, with reference to the 
available anatomical sequences, and copied onto the parametric maps. The mean and 
standard deviation of the quantified parameters were recorded for each case. 
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MRE Quality Assessment 
Parametric maps of data ‘non-linearity’, displaying the percentage deviation of the phase 
signal from a perfect sinusoidal modulation, were assessed by both readers for each MRE 
measurement, using the same ROI as previously, and the mean ‘non-linearity’ percentage 
documented. A threshold of <50% mean ‘non-linearity’ was defined as acceptable data 
quality. 
Anatomical and Functional MR Imaging 
Anatomical imaging included a T2-weighted half-Fourier single-shot turbo spin echo 
sequence (HASTE) (TR, 1000 msec; TE, 97 msec; FA, 135°; NEX, 1; GRAPPA parallel imaging 
acceleration factor, 2; FOV, 384 x 250 mm; pixel size, 1.5 x 1.2 x 3.0 mm) acquired in the 
axial plane.  
Dynamic contrast-enhanced (DCE) MR imaging was based on a 3D T1-weighted axial 
volumetric interpolated spoiled gradient echo sequence (VIBE) (TR, 4.62 msec; TE, 1.72 
msec; FA, 18°; number of signals acquired, 1; parallel imaging acceleration factor, 2; FOV, 
300 x 244 mm; pixel size, 1.8 x 1.3 x 4.0 mm). 0.1 mmol/kg of gadolinium contrast agent was 
administered intravenously (Gadovist®, Bayer) at a rate of 4 mL/sec using a power injector, 
followed by a 20 mL saline chaser; 30 volumes were acquired post contrast injection over 3 
minutes, resulting in a temporal resolution of 6.4 sec. The dynamic acquisition was preceded 
by a T1 calibration sequence with the same parameters except a flip angle of 3°. 
Diffusion-weighted imaging consisted of free-breathing single-shot echo-planar imaging in 
the axial plane with b values of 50, 500 and 800 mm2/sec. Imaging parameters were as 
follows: TR, 6100 msec; TE, 62 msec; NEX, 5; parallel imaging acceleration factor, 2; FOV, 
380 x 285 mm; pixel size 3.7 x 3.0 x 4.0 mm.  
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Anatomical and functional sequences were post processed and analyzed offline on a 
commercial platform (Multimodality Workplace, Siemens). All quantitative measurements 
were performed by a single radiologist (MRE observer 1), blinded to histopathology. 
Freehand ROI were drawn on each slice displaying the lesion of interest; volumetric means 
were analyzed. T2 signal intensity (SI) ratio was calculated as the % ratio of tumor over renal 
cortex on the T2 HASTE sequence (8). 
DCE MR imaging parametric maps, including transfer coefficient (Ktrans), rate constant (kep), 
extracellular-extravascular space fractional volume (ve) and initial area under the 
concentration curve for the first 60 seconds (iAUC60), were generated on dedicated software 
(Tissue 4D; Siemens); nonrigid motion correction and registration to the calibration 
sequence were applied to the dynamic acquisition; quantification was based on the two-
compartment Tofts model (31), using a pre-set population averaged arterial input function. 
Apparent diffusion coefficient (ADC) maps were generated by fitting a mono-exponential 
function to all b values.  
Statistics 
All statistical analyses were performed using IBM SPSS version 23.0 software. Continuous 
variables were regarded as non-normally distributed and expressed as medians and 
interquartile range. Measurements were compared between the two main histological 
groups using the non-parametric Mann-Whitney U test. Mean interobserver MRE values 
were used in the analysis. P < .05 was considered indicative of a significant difference. 
Interobserver agreement was assessed using Bland-Altman (BA) statistics and intraclass 
correlation coefficients (ICC). MRE within-subject variability in healthy renal parenchyma 
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was expressed in terms of mean differences and coefficients of variance (CV). Missing data 
were omitted from the analysis. 
Results 
One patient did not complete imaging due to claustrophobia, leaving 20 complete imaging 
datasets including MRE. Surgical histopathology became available for 19 patients and 
revealed 4 renal oncocytomas, 12 ccRCC (1, Fuhrman grade 3; 8, grade 2; 3, grade 1), 2 
papillary RCC and 1 metanephric adenoma. One further case of renal oncocytoma was 
diagnosed from image-guided biopsy and surgery was deferred. Tumor diameters ranged 
between 2.2 and 5.0 cm. All imaging sessions were completed in less than 60 minutes. 
MRE of Tumors 
Two tumor MRE datasets were excluded for insufficient quality, secondary to poor patient 
compliance with breath hold instructions and consequent high data non-linearity (>50%), 
leaving a cohort of 11 clear cell renal cell carcinomas (ccRCC) and 5 oncocytomas for 
statistical analysis. 
Shear wave velocity c was significantly lower in oncocytomas (median, 0.77 m/s; 
interquartile range (IQR), 0.76-0.79) than in ccRCC (median, 0.92 m/s; IQR, 0.84-0.97) (P = 
0.007). Shear wave attenuation α was significantly higher in oncocytomas (median, 0.087 
mm-1; IQR, 0.082-0.087) than in ccRCC (median, 0.066 mm-1; IQR, 0.054-0.074) (P = 0.008). 
Complete results, including case-by-case mean values and standard deviations, are reported 
in Table 1. Pictorial examples are shown in Figure 1. Oncocytomas displayed a relatively 
narrow range of values (c range, 0.71-0.83 m/s; α range, 0.082-0.093 mm-1), corresponding 
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to data point clustering in a bidimensional scatter plot (Figure 2). ccRCC had wider ranges (c 
range, 0.79-1.11 m/s; α range, 0.046-0.083 mm-1), resulting in a broader data point scatter. 
The only papillary RCC imaged with sufficient data quality showed relatively low c (0.77 m/s, 
coinciding with the median value of oncocytomas) and low α (0.064 mm-1, close to the 
median of ccRCC). Metanephric adenoma displayed relatively low c (0.78 m/s) and 
intermediate α (0.079 mm-1). 
MRE Interobserver Agreement 
Mean ROI size was 226 ± 109 pixels for observer 1 and 196 ± 102 pixels for observer 2. 
Mean differences in tumors were 0.002 m/s [c] and -0.0005 mm-1 [α]. Bland-Altman limits of 
agreement were the mean differences as previously ± 0.055 m/s [c] and ± 0.0077 mm-1 [α] 
respectively (Figure 3). ICC (95% confidence intervals) were 0.982 (0.953-0.993) [c] and 
0.984 (0.957-0.994) [α], indicating excellent agreement. 
MRE of Normal Kidney 
A total of 31 MRE measurements of acceptable quality were performed in normal portions 
of the tumor-containing kidneys. Mean shear velocity c in the renal parenchyma was 0.89 ± 
0.10 m/s; mean shear attenuation α was 0.072 ± 0.012 mm-1. 
Two separate measurements in different portions of the same kidney were acquired in a 
subset of 10 patients. Mean within-subject differences were 0.10 ± 0.05 m/s for c and 0.014 
± 0.010 mm-1 for α, corresponding to CV of 7.81 ± 4.61% and 14.24 ± 10.72% respectively. 
Anatomical and Functional MR Imaging of Tumors 
Tumor parametric values are reported in Table 1. Oncocytomas had significantly lower T2 SI 
ratio (median, 93%; interquartile range, 89-93%) than ccRCC (median, 120%; interquartile 
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range, 103-128%) (P = 0.020). No statistically significant difference between the two 
histological groups was observed among functional MR imaging parameters. Oncocytomas 
appeared on average more vascular on DCE MR imaging, with higher iAUC60 (median, 59 
mmol; P = 0.100), Ktrans (median, 0.24 min-1; P = 0.126), kep (median, 0.66 min-1; P = 0.193) 
and lower ve (median, 0.30 mL/100 mL; P = 0.692). ADC varied considerably within both 
groups, being on average lower in oncocytomas (median, 1363 x 10-6 mm2/s) (P = 0.193). 
Both papillary RCC displayed markedly restricted diffusion (ADC = 839 and 959 x 10-6 mm2/s) 
and low T2 SI ratios (74% and 55%), in line with the existing literature (32, 33). The 
metanephric adenoma showed relatively low T2 SI ratio (58%) and contrast enhancement 
(iAUC60 = 19 mmol)(34). Only partial data point clustering was obtained by plotting T2 SI 
ratio against ADC (Figure 2B). No clustering was observed by plotting DCE MR Ktrans against 
ve (Figure 2C). 
Among qualitative anatomical tumor features, a T2 pseudocapsule was present in 2 out of 5 
oncocytomas and 10 out of 12 ccRCC; central T2 hyperintensity was observed in 3 
oncocytomas and 1 ccRCC; and signal drop on opposed-phase chemical shift MRI in no 
oncocytoma and 7 ccRCC. 
Discussion 
Our study shows that MRE is feasible, as part of a multiparametric MR protocol, for the 
characterization of small indeterminate renal tumors and represents a promising technique 
for distinguishing benign oncocytoma from malignant clear cell carcinoma. MRE shear 
velocity c and shear attenuation α were the strongest imaging discriminators between 
oncocytoma and ccRCC in this initial prospective cohort of 20 patients. 
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Identifying renal oncocytoma among indeterminate SRT is problematic based on imaging 
alone, even using multiparametric MR, as highlighted by current literature. Among 
anatomical MR imaging parameters, T2 signal intensity has been shown to be higher in 
ccRCC than in oncocytoma and chromophobe RCC, but the overlap is substantial (35, 36). T2 
SI ratio was in fact the third best discriminator between oncocytoma and ccRCC in our study. 
The presence of a central area of T2 signal hyperintensity, compatible with necrosis or 
fibrosis, can be observed in both oncocytoma and RCC (8, 9). Chemical shift MR, combined 
with delayed contrast enhanced imaging, has been found to have a high negative predictive 
value for oncocytoma (97%), by revealing the typical absence of fat and the presence of 
enhancing central fibrosis: these findings, however, have yet to be validated prospectively 
(10). A T2 hypointense pseudocapsule, commonly observed in SRT, is also nonspecific (16). 
Diffusion and contrast enhancement characteristics can discriminate between types of RCC 
but again are known to overlap between oncocytoma and ccRCC (32, 37); this was the case 
in our cohort, where DCE MR iAUC60 was the strongest functional discriminator (P = .10), 
being higher in oncocytomas. Taouli et al. previously found significantly lower ADC values in 
solid ccRCC than in oncocytomas, but only after excluding Bosniak 4 ccRCC (i.e. solid masses 
with a large cystic or a necrotic component), potentially indistinguishable from oncocytoma 
in our experience (11). No significant signal intensity change was observed by Vargas et al. 
on contrast-enhanced MR between ccRCC and oncocytoma in any phase of enhancement 
(12). 
To our knowledge, this study is the first to investigate the viscoelastic properties of SRT 
using MRE. Published reports employing semiquantitative (strain) or quantitative (shear-
wave) ultrasound elastography techniques for differentiating benign from malignant renal 
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tumors found RCC to be stiffer than benign lesions such as angiomyolipoma; no 
oncocytomas were included, however (38-40). 
Our results support the hypothesis that differences in tumor composition and structural 
architecture, clearly distinguishable on histopathology between oncocytoma and RCC, are 
reflected by MRE viscoelastic shear properties. Oncocytomas showed lower shear wave 
velocity, corresponding to lower stiffness (storage modulus), and higher shear attenuation 
(loss modulus), corresponding to higher viscosity, than ccRCC.  This is in line with the 
evidence that malignancy increases stiffness through collagen deposition in the extracellular 
matrix and raised interstitial pressure levels from the altered vasculature (41, 42). Lower 
MRE stiffness values in benign versus malignant tumors have been documented in the 
breast and in the liver (23, 26, 43, 44). 
Few studies to date have assessed tumors in terms of shear wave attenuation. The loss 
modulus was found to be significantly higher in hepatocellular carcinoma than in benign 
liver tumors (hemangioma, focal nodular hyperplasia, adenoma) by Garteiser et al. (23), 
contrasting with our results. We speculate that the higher shear wave attenuation values 
measured in oncocytoma might reflect a high density of capillaries with normal 
endothelium, resulting in efficient energy dispersion in the form of heat and contrasting 
with the disorganized vasculature and leaky endothelium typical of renal carcinomas.  
Propagating waves could be appreciated on phase images in all MRE acquisitions. Two out 
of 20 datasets were excluded for insufficient quality, defined as nonlinearity >50%. In one 
case (ccRCC-07, Table 1), respiratory motion was identified as the main causative factor 
from the presence of blurred renal contours on the magnitude images. In the second case 
(papRCC-02) (Figure 4), wave penetration inside the lesion was inconsistent with an 
incompressible material (as if detached from the surrounding tissue) despite good 
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penetration in the adjacent kidney; this was a hemorrhagic papillary RCC showing marked 
signal hypointensity on T2 HASTE. Interestingly, one of the main causes identified by 
Wagner et al. for technical MRE failure in the liver at 3T (45) was hepatic iron deposition, 
causing shortening of T2* relaxation. Intratumoral hemorrhage is frequent in papillary RCC, 
but is not known to occur in oncocytoma; low ADC values are the dominant MR feature of 
papillary RCC and in our experience it seems unlikely that MRE will be the main determinant 
for papillary RCC characterization. 
The average level of phase signal nonlinearity was ~30% throughout MRE acquisitions, 
corresponding to our previous clinical experience using the Resoundant® system in the 
upper abdomen. New bespoke transducers, based upon a gravitational concept for 
generating shear waves (46), are expected to lower this level and thereby increase the 
reproducibility of viscoelastic parameters. MRE interobserver limits of agreement (mean 
difference ± 0.055 m/s [c] and ± 0.0077 mm-1 [α]) were deemed within acceptable limits and 
appear unlikely to affect the significance of between-group differences.  
Of the two MRE parameters, c was less dispersed around the mean value in tumor ROI: SD 
ranged between 0.11 and 0.30 m/s (Table 1), corresponding to a CV of ~14-28%. MRE c SD 
were noticeably lower in oncocytomas than ccRCC; this was not the case for MRE α or 
anatomical/functional MR imaging parameters. Within-subject variability in healthy renal 
parenchyma was 7.81 ± 4.61% for c and 14.24 ± 10.72% for α. Similarly, Rouviere et al. (47) 
found a mean shear wave velocity variation of 6% (range, 2 - 16%) between two 
independent measurements in the kidney of young healthy adults at 45 Hz, also using a 
gradient echo sequence at 1.5 T. Although not directly comparable, a recent meta-analysis 
on MRE repeatability in the liver identified a measured change in hepatic stiffness of 22% or 
greater as a reliable true change (95% confidence) (48). 
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Despite our promising results, our study does have limitations: the small study cohort 
reflects its exploratory nature and does not allow us to draw definitive conclusions on the 
diagnostic accuracy of MR imaging parameters. Prospective recruitment of consecutive 
patients from a single tertiary clinic meant that only the most common SRT histologies were 
captured. The decision to include tumors ≤ 5 cm in diameter (contrasting with the 
conventional definition of small renal mass, ≤ 4 cm) was made to facilitate patient 
recruitment. Less common histologies such as chromophobe RCC, often morphologically 
indistinguishable from oncocytoma (36), and fat poor AML (35) were not part of our 
prospective cohort. 
In conclusion, MRE is feasible and practicable for the characterization of small 
indeterminate renal tumors as part of a multiparametric MR protocol. This feasibility study 
highlights the diagnostic potential of MRE for distinguishing renal oncocytoma from ccRCC, 
strengthening the case for confirmation of these results in a powered diagnostic accuracy 
study. 
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Tables 
Table 1. Results from tumor multiparametric MR imaging, displayed by tumor histology.  
Note. Tumor diameters as measured at surgical histopathology. Mean values ± standard 
deviation. P values for between-group comparisons were determined with the Mann-
Whitney U test. IQR = interquartile range. - = missing value. 
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Case # Diameter (cm) c (m/s) α (mm-1) iAUC60 (mmol) Ktrans (min-1) Kep (min-1) Ve (mL/100 mL) T2 SI RATIO (%) 
ADC (10-6 x 
mm2/s) 
RENAL ONCOCYTOMA 
ONCO-1 4.2 0.83 ± 0.16 0.093 ± 0.033 72 ± 34 0.31 ± 0.17 0.99 ± 0.37 0.30 ± 0.14 93 ± 30 1949 ± 338 
ONCO-2 5.0 0.79 ± 0.16 0.082 ± 0.035 32 ± 16 0.09 ± 0.05 0.32 ± 0.16 0.28 ± 0.15 86 ± 27 1319 ± 260 
ONCO-3 5.0 0.77 ± 0.14 0.082 ± 0.048 80 ± 38 0.41 ± 0.24 1.15 ± 0.58 0.33 ± 0.17 89 ± 24 1348 ± 284 
ONCO-4 3.1 0.76 ± 0.11 0.087 ± 0.044 59 ± 22 0.24 ± 0.10 0.62 ± 0.23 0.39 ± 0.14 124 ± 40 1961 ± 315 
ONCO-5 4.5 0.71 ± 0.11 0.087 ± 0.042 51 ± 32 0.20 ± 0.13 0.66 ± 0.26 0.29 ± 0.16 93 ± 30 1363 ± 231 
Median (IQR) 4.5 (4.2-5.0) 
0.77 (0.76-
0.79) 
0.087 (0.082-
0.087) 
59 (51-72) 0.24 (0.20-0.31) 0.66 (0.62-0.99) 0.30 (0.29-0.33) 93 (89-93) 
1363 (1348-
1949) 
CLEAR CELL RENAL CELL CARCINOMA 
ccRCC-01 3.3 1.00 ± 0.28 0.060 ± 0.027 29 ± 20 0.11 ± 0.09 0.47 ± 0.30 0.24 ± 0.17 126 ± 40 1760 ± 326 
ccRCC-02 3.0 0.79 ± 0.12 0.072 ± 0.054 63 ± 29 0.21 ± 0.10 0.51 ± 0.15 0.40 ± 0.17 106 ± 23 1590 ± 184 
ccRCC-03 3.6 0.83 ± 0.16 0.070 ± 0.040 50 ± 43 0.19 ± 0.20 0.41 ± 0.36 0.33 ± 0.30 101 ± 34 1695 ± 365 
ccRCC-04 2.8 0.94 ± 0.19 0.066 ± 0.035 55 ± 34 0.22 ± 0.17 0.74 ± 0.46 0.29 ± 0.17 102 ± 31 1722 ± 320 
ccRCC-05 2.5 0.84 ± 0.23 0.083 ± 0.045 46 ± 32 0.17 ± 0.13 0.33 ± 0.23 0.45 ± 0.26 141 ± 44 2118 ± 394 
ccRCC-06 3.0 0.86 ± 0.18 0.085 ± 0.030 23 ± 22 0.09 ± 0.09 0.63 ± 1.42 0.18 ± 0.17 121 ± 37 1929 ± 303 
ccRCC-07 2.7 - - 62 ± 44 0.24 ± 0.18 0.62 ± 0.38 0.33 ± 0.23 94 ± 32 1433 ± 255 
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ccRCC-08 3.5 1.11 ± 0.30 0.052 ± 0.032 27 ± 21 0.11 ± 0.09 0.30 ± 0.24  0.38 ± 0.27 152 ± 47 2483 ± 424 
ccRCC-09 4.2 0.92 ± 0.24 0.046 ± 0.033 61 ± 31 0.27 ± 0.16 0.71 ± 0.28 0.37 ± 0.20 124 ± 45 1512 ± 460 
ccRCC-10 4.0 0.93 ± 0.19 0.032 ± 0.022 47 ± 43 0.19 ± 0.18 0.68 ± 0.56 0.26 ± 0.24 104 ± 35 1795 ± 295 
ccRCC-11 3.4 1.00 ± 0.23 0.075 ± 0.050 29 ± 21 0.11 ± 0.09 0.38 ± 0.38 0.30 ± 0.19 120 ± 54 1984 ± 348 
ccRCC-12 2.2 0.80 ± 0.14 0.056 ± 0.028 51 ± 19 0.15 ± 0.07 0.30 ± 0.15 0.49 ± 0.22 134 ± 39 1612 ± 155 
Median (IQR) 3.2 (2.8-3.5) 
0.92 (0.84-
0.97) 
0.066 (0.054-
0.074) 
48 (29-57) 0.18 (0.11-0.21) 0.49 (0.36-0.64) 0.33 (0.28-0.39) 120 (103-128) 
1741 (1606-
1943) 
P value .017 .007 .008 .100 .126 .193 .692 .020 .193 
PAPILLARY RENAL CELL CARCINOMA 
papRCC-01 3.7 0.77 ± 0.10 0.062 ± 0.029 30 ± 20 0.11 ± 0.10 0.68 ± 0.40 0.17 ± 0.14 74 ± 17 839 ± 218 
papRCC-02 4.1 - - 15 ± 19 0.06 ± 0.04 0.50 ± 0.55 0.16 ± 0.10 55 ± 35 959 ± 602 
METANEPHRIC ADENOMA 
MA-01 5.0 0.78 ± 0.15 0.079 ± 0.033 19 ± 12 0.11 ± 0.07 0.17 ± 0.20 0.37 ± 0.21 58 ± 14 1222 ± 339 
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Figure Captions 
Figure 1. A. Fuhrman grade 2, 2.7 cm ccRCC in a 67-year-old man. B. 3.1 cm renal 
oncocytoma in a 51-year-old man. Axial MR imaging sections. Anatomical T2 HASTE (top 
left), ADC map (middle), cortico-medullary phase contrast-enhanced T1 VIBE (top right), 
MRE magnitude image (bottom left), MRE c (middle) and MRE α (bottom right) parametric 
maps. Morphological and functional imaging features are indistinguishable between the two 
histologies. Oncocytoma displays relatively lower shear velocity c and higher shear 
attenuation α. Tumors are contoured in red on MRE magnitude images and parametric 
maps. The adjacent kidney is contoured in pink and can be clearly distinguished from the 
surrounding structures on MRE shear velocity maps. 
Figure 2. Bidimensional scatter plots of tumor MR imaging parameters. Oncocytomas 
display a consistent MRE viscoelastic profile, corresponding to data point clustering (A). Only 
partial clustering is obtained by plotting T2 SI ratio against ADC (B). No clustering is 
observed by plotting DCE MR Ktrans against ve (C). 
Figure 3. Interobserver agreement. Bland-Altman graphs of MRE c (left) and α (right), 
plotting interobserver differences against their mean. Red dotted lines represent 95% 
Bland-Altman limits of agreement; blue line represents the mean difference. 
Figure 4. Type 1, 4.1 cm papillary RCC in a 66-year-old man: axial MR imaging sections. 
Anatomical T2 HASTE (left), MRE gradient-echo magnitude image (middle) and MRE non-
linearity parametric map (right). Intra-tumoral haemorrhage, confirmed at histology, 
corresponds to low signal intensity in A and B.  MRE phase signal shows elevated non-
linearity within the tumor (~80%) compared to adjacent renal parenchyma (~35%). 
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